Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

Withdrawn before enrolling · Phase 2

Conditions studied: Leukemia

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Combining more than one chemotherapy drug with biological therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, isotretinoin, and interferon alfa in treating patients who have acute myelogenous leukemia.

Key facts

Study ID

NCT00003405

Run by

Rush University Medical Center

People needed

0

Starts

1998-04-01

Expected to finish

1999-04-01

Last updated by the study team

2021-10-14

Who can join

Age: any, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cook County Hospital — Chicago, Illinois, United States
• Rush Cancer Institute — Chicago, Illinois, United States
• Angelo P. Creticos, M.D. Cancer Center — Chicago, Illinois, United States
• Rush-Riverside Cancer Center — Kankakee, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.